Last reviewed 2026-04-20 · How we verify

Ga-68-DOTATOC

Ga-68-DOTATOC is a radiopharmaceutical used primarily for diagnostic imaging in neuroendocrine tumors (NETs). It is not approved by the FDA but is used under research protocols. The drug binds to somatostatin receptors, allowing for the visualization of NETs. Despite its lack of FDA approval, it has shown promise in clinical trials and is being evaluated for broader use. Safety data from clinical trials indicate that it is generally well-tolerated, with minimal side effects. However, due to its radioactive nature, specific precautions must be taken.

At a glance

Approved indications

No approved indications tracked.

Pipeline indications

Common side effects

• Nausea
• Pruritus
• Flushing

Serious adverse events

• Hypersensitivity reactions
• Anaphylaxis
• Angioedema

Key clinical trials

• Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells (PHASE2)
• Combination External Radiation and PRRT for Large GI Neuroendocrine Tumors. (PHASE1)
• Direct Comparison of Ga-68-DOTATATE and Ga-68-DOTATOC (PHASE2)
• An Investigational Scan (68Ga-DOTATATE PET/CT) in Diagnosing Pediatric Metastatic Neuroendocrine Tumors (EARLY_PHASE1)
• RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma (PHASE1, PHASE2)
• Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy (PHASE2)
• 177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer (PHASE2)
• Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.